We are pleased to announce that Biomica, a subsidiary of Evogene, has entered into an exclusive worldwide licensing agreement with Lishan Biotech for BMC128, a microbiome-based therapeutic for renal and lung cancer that has successfully completed its Phase 1 clinical trial.
Read the full press release here.
Read the full press release here
As part of this transition, the Biomica website is no longer active.
For more information, please visit www.evogene.com or contact us at info@evogene.com
